Impact of exercise on chemotherapy-induced peripheral neuropathy in survivors with post-treatment primary breast cancer Journal Article

  


Authors: Saint, K.; Nemirovsky, D.; Lessing, A.; Chen, Y.; Yang, M.; Underwood, W. P.; Galantino, M. L.; Jones, L. W.; Bao, T.
Article Title: Impact of exercise on chemotherapy-induced peripheral neuropathy in survivors with post-treatment primary breast cancer
Abstract: Purpose Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect of neurotoxic chemotherapy. Exercise activates neuromuscular function and may improve CIPN. We examined the association between exercise and CIPN symptoms in breast cancer survivors. Methods In a retrospective cross-sectional study, we included patients completing a survey assessing exercise exposure and neuropathy symptoms in a tertiary cancer center survivorship clinic. We evaluated exercise duration and intensity using a standardized questionnaire quantified in metabolic equivalent tasks (MET-h/wk). We defined exercisers as patients meeting the National Physical Activity Guidelines' criteria. We used multivariable logistic regressions to examine the relationship between exercise and CIPN and if this differed as a function of chemotherapy regimen adjusting for age, gender, and race. Results We identified 5444 breast cancer survivors post-chemotherapy (median age 62 years (interquartile range [IQR]: 55, 71); median 4.7 years post-chemotherapy (IQR: 3.3, 7.6)) from 2017 to 2022. CIPN overall prevalence was 34% (95% confidence interval [CI]: 33%, 36%), 33% for non-taxane, and 37% for taxane-based chemotherapy. CIPN prevalence was 28% (95% CI: 26%, 30%) among exercisers and 38% (95% CI: 37%, 40%) among non-exercisers (difference 11%; 95% CI: 8%, 13%; p < 0.001). Compared to patients with low (<6 MET-h/wk) levels of exercise (42%), 11% fewer patients with moderate (6-20.24 MET-h/wk) to high (>20.25 MET-h/wk) levels of exercise reported CIPN. Exercise was associated with reduced prevalence of all CIPN symptoms regardless of chemotherapy type. Conclusion CIPN may persist several years following chemotherapy among patients with breast cancer but is significantly reduced by exercise in a dose-dependent manner.
Keywords: prevalence; risk; symptom; management; chemotherapy-induced peripheral neuropathy; physical-activity; prevention; breast cancer survivors; physical exercise
Journal Title: Breast Cancer Research and Treatment
Volume: 206
Issue: 3
ISSN: 0167-6806
Publisher: Springer  
Date Published: 2024-08-01
Start Page: 667
End Page: 675
Language: English
ACCESSION: WOS:001215569000001
DOI: 10.1007/s10549-024-07342-6
PROVIDER: wos
PUBMED: 38713289
Notes: Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- Source: Wos
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Lee Winston Jones
    177 Jones
  2. Whitney Paige Underwood
    7 Underwood
  3. Yuan Chen
    38 Chen
  4. David Nemirovsky
    41 Nemirovsky
Related MSK Work